Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.

Published

Journal Article

Striae distensae (stretch marks) are a common complication seen in patients on chronic corticosteroid therapy. Under certain circumstances, primary brain tumor patients require chronic corticosteroid therapy and can suffer from striae distensae. Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor-A (VEGF-A) is now more widely used for the treatment of primary brain tumors. In this paper, we present four cases of ulcerated striae distensae in primary brain tumor patients on concurrent corticosteroid and bevacizumab therapy. Because of bevacizumab's effects on wound healing and its recent accelerated approval for recurrent glioblastoma multiforme (GBM), the most common malignant primary brain tumor in adults, this novel skin complication should be considered in patients on concurrent corticosteroid and bevacizumab therapy.

Full Text

Duke Authors

Cited Authors

  • Peters, KB; Coyle, TE; Vredenburgh, JJ; Desjardins, A; Friedman, HS; Reardon, DA

Published Date

  • January 2011

Published In

Volume / Issue

  • 101 / 1

Start / End Page

  • 155 - 159

PubMed ID

  • 20524043

Pubmed Central ID

  • 20524043

Electronic International Standard Serial Number (EISSN)

  • 1573-7373

International Standard Serial Number (ISSN)

  • 0167-594X

Digital Object Identifier (DOI)

  • 10.1007/s11060-010-0239-0

Language

  • eng